Get the Stockscreener App
0.66
3.93%
-0.027
Pre-market:
.69
0.03
+4.55%
Scynexis Inc stock is traded at $0.66, with a volume of 419.46K.
It is down -3.93% in the last 24 hours and down -14.29% over the past month.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
See More
Previous Close:
$0.687
Open:
$0.6897
24h Volume:
419.46K
Relative Volume:
1.03
Market Cap:
$27.67M
Revenue:
$3.26M
Net Income/Loss:
$-19.52M
P/E Ratio:
-1.65
EPS:
-0.4
Net Cash Flow:
$-24.10M
1W Performance:
-14.29%
1M Performance:
-14.29%
6M Performance:
-33.19%
1Y Performance:
-51.47%
1-Day Range:
$0.6496
$0.691
1-Week Range:
$0.6496
$0.786
52-Week Range:
$0.6496
$1.49
Scynexis Inc Stock (SCYX) Company Profile
Name
Scynexis Inc
Sector
Phone
201-884-5485
Address
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Compare SCYX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
0.66 | 28.80M | 3.26M | -19.52M | -24.10M | -0.40 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-21 | Initiated | Guggenheim | Buy |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-18 | Upgrade | Needham | Hold → Buy |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-10-17 | Initiated | ROTH Capital | Buy |
| May-09-17 | Downgrade | Needham | Buy → Hold |
| Mar-03-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-20-16 | Initiated | H.C. Wainwright | Buy |
| Oct-07-16 | Upgrade | WBB Securities | Buy → Strong Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Aug-17-16 | Initiated | Guggenheim | Buy |
| Aug-09-16 | Reiterated | Needham | Buy |
| Aug-09-16 | Upgrade | WBB Securities | Speculative Buy → Buy |
| Mar-28-16 | Initiated | Brean Capital | Buy |
| Dec-29-15 | Initiated | WBB Securities | Speculative Buy |
| Nov-16-15 | Reiterated | RBC Capital Mkts | Outperform |
| Jun-10-15 | Initiated | Needham | Buy |
| May-29-14 | Initiated | Canaccord Genuity | Buy |
| May-29-14 | Initiated | RBC Capital Mkts | Outperform |
View All
Scynexis Inc Stock (SCYX) Latest News
Can SCYNEXIS Inc. stock maintain growth trajectoryQuarterly Portfolio Report & Breakout Confirmation Trade Signals - newser.com
Analyzing recovery setups for SCYNEXIS Inc. investorsRecession Risk & Safe Entry Trade Signal Reports - newser.com
How interest rate cuts could boost SCYNEXIS Inc. stockTrade Volume Summary & High Accuracy Trade Signal Alerts - newser.com
Live market analysis of SCYNEXIS Inc.July 2025 Spike Watch & Safe Entry Point Identification - newser.com
Why SCYNEXIS Inc. (135A) stock benefits from AI revolutionJuly 2025 Spike Watch & High Yield Stock Recommendations - newser.com
Will SCYNEXIS Inc. stock recover faster than peers2025 Historical Comparison & Consistent Growth Stock Picks - newser.com
Why SCYNEXIS Inc. (135A) stock stays resilient2025 Historical Comparison & Fast Gain Stock Trading Tips - newser.com
Does SCYNEXIS Inc. fit your quant trading modelMarket Volume Report & Safe Entry Point Alerts - newser.com
How supply chain issues affect SCYNEXIS Inc. stockForecast Cut & AI Based Buy and Sell Signals - newser.com
How to build a dashboard for SCYNEXIS Inc. stockExit Point & Expert Approved Momentum Ideas - newser.com
Is SCYNEXIS Inc. stock bottoming outMarket Sentiment Report & Daily Profit Focused Screening - newser.com
Should I hold or sell SCYNEXIS Inc. stock in 20252025 Market Sentiment & Free Technical Confirmation Trade Alerts - newser.com
SCYNEXIS Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
How SCYNEXIS Inc. (135A) stock performs in volatility spikes2025 Trade Ideas & Reliable Intraday Trade Plans - newser.com
Will SCYNEXIS Inc. continue its uptrendJuly 2025 Summary & Daily Technical Forecast Reports - newser.com
Is SCYNEXIS Inc. stock ready for a breakout2025 Performance Recap & Weekly High Momentum Picks - newser.com
How geopolitical tensions affect SCYNEXIS Inc. stock2025 Institutional Moves & Fast Momentum Stock Entry Tips - newser.com
Guggenheim Lowers Price Target for SCYNEXIS (SCYX) but Maintains Buy Rating | SCYX Stock News - GuruFocus
Guggenheim lowers SCYNEXIS stock price target to $3 after GSK trial resolution - Investing.com
Scynexis Inc Stock (SCYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.18%
1.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):